Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem	⤷ Get Started Free	B1243062	⤷ Get Started Free
THE BioTek	⤷ Get Started Free	bt-1576095	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 31, 2025

Introduction

TACONEX, a widely utilized medication for psoriasis, is synthesized with the active pharmaceutical ingredient (API) Tazarotene. As a retinoid analog, Tazarotene's quality, purity, and consistency directly influence the efficacy, safety, and regulatory approval of TACONEX formulations. The sourcing of bulk APIs is fundamental to pharmaceutical manufacturing, impacting supply chain stability, cost, and compliance with regulatory standards. This article provides an in-depth analysis of primary and secondary sources of Tazarotene API, market dynamics, key manufacturing players, and considerations for pharmaceutical companies seeking reliable API suppliers.

Overview of Tazarotene API

Tazarotene is a third-generation topical retinoid primarily used for psoriasis and acne vulgaris. Chemically, it is a retinoic acid derivative with a distinctive structure tailored to modulate keratinocyte proliferation and differentiation. The API's stability and purity thresholds necessitate strict quality controls during manufacturing and sourcing. Given its application on the skin, the API must adhere to stringent standards governing residual solvents, heavy metals, and microbial impurities.

Primary Sources of Tazarotene API

1. Major Global API Manufacturers

Several established pharmaceutical companies dominate the manufacturing landscape of Tazarotene API. Their production capabilities, compliance standards, and strategic partnerships shape the global supply network.

a. United States and Europe

Lonza Group (Switzerland): Known for high-quality chemical synthesis and robust quality assurance standards, Lonza supplies a range of APIs, including Tazarotene, with consistent purity profiles suitable for top-tier pharmaceutical formulations.
Siegfried AG (Switzerland): A leading manufacturer specializing in high-potency APIs, Siegfried provides Tazarotene to global markets, emphasizing rigorous GMP compliance.
Dr. Reddys Laboratories (India): While primarily focused on bulk generics, Dr. Reddys offers Tazarotene APIs with competitive pricing, ensuring compliance with international standards.

b. Asian Market Leaders

Hester Biosciences Ltd. (India): Focuses on precursors and intermediates for dermatological APIs; their manufacturing facilities are approved by global regulatory agencies.
CIPLA (India): With an extensive API portfolio, Cipla produces Tazarotene compliant with GMP standards, catering mainly to the Asian and emerging markets.
Zhejiang Hisun Pharmaceuticals (China): Manufactures multiple retinoid APIs, including Tazarotene, with increasing regulatory approvals for global distribution.

2. Contract Manufacturing and OEM Options

Companies lacking internal API production capabilities often source fromContract Development and Manufacturing Organizations (CDMOs).

Teva Pharmaceuticals: Offers supply of Tazarotene APIs sourced from approved facilities, emphasizing regulatory compliance.
Cambridge Major Laboratories (now part of CCEM): Provides custom synthesis of Tazarotene API, with quality tailored to client specifications.
Boehringer Ingelheim: Supports contract manufacturing of retinoid APIs, including APIs suitable for dermatological applications.

3. API Intermediates and Precursor Suppliers

The quality of the Tazarotene API heavily depends on the intermediates used in its synthesis, notably:

4-[(2,6-dichlorobenzoyl)amino]benzoic acid derivatives.
Critical reagents, such as specific acyl chlorides or ketones, procured from specialty chemical suppliers ensuring purity and consistency.

4. Emerging Markets and Local Suppliers

In response to increasing demand, regional suppliers in India, China, and Southeast Asia are scaling up API production. These suppliers often compete on cost but may require rigorous vetting to meet international quality standards.

Criteria for Selecting API Suppliers

When sourcing Tazarotene API, pharmaceutical companies prioritize the following:

Regulatory compliance: GMP certification, WHO-GMP, USFDA, EMA approval status.
Quality attributes: Purity (>98%), residual solvent limits, batch-to-batch consistency.
Supply stability: Ability to meet demand fluctuations and contingency planning.
Pricing and lead times: Competitive cost structures, reliable delivery schedules.
Traceability and documentation: Complete batch records, Certificates of Analysis (CoA), and compliance documentation.

Current Market Trends and Challenges

Supply Chain Disruptions

Recent global events, notably the COVID-19 pandemic, have underscored vulnerabilities in pharmaceutical supply chains. API shortages have affected production schedules, leading to increased reliance on alternate suppliers or regional sources.

Regulatory Stringency

Regulatory authorities increasingly scrutinize API manufacturing processes, emphasizing Documentation, quality control, and environmental practices. Suppliers lacking in GMP compliance risk market exclusion.

Cost Pressure and Market Competition

Price competition influences sourcing strategies, especially from emerging economies. While lower costs are attractive, they often come with trade-offs regarding regulatory acceptance and quality assurances.

Intellectual Property Considerations

Although Tazarotene's formulations are generally off-patent, API manufacturers must navigate patent landscapes and licensing agreements, especially when sourcing from third parties.

Regulatory and Quality Assurance Considerations

The pharmaceutical industry mandates APIs meet international quality standards, notably:

USP/NF, EP, JP, or WHO monographs for Tazarotene.
Batch validation, stability data, and impurity profiling.
Inspection reports and audit compliance from manufacturing facilities.

Ensuring that API sources comply with these standards minimizes regulatory hurdles and enhances product credibility.

Future Outlook and Developments

The API sourcing landscape for Tazarotene is poised to evolve with:

Increased investment in vertical integration by leading pharmaceutical firms.
Adoption of continuous manufacturing processes improving quality and yield.
Stringent environmental and safety regulations prompting cleaner processes.
Expansion of regional manufacturing capacity, reducing reliance on a limited number of global suppliers.

Key Takeaways

Diversity of Sources: Key global players like Lonza, Siegfried, and Dr. Reddys dominate Tazarotene API supply, complemented by emerging suppliers in Asia. Diversification reduces supply risks.
Regulatory Conformance: Strict adherence to GMP and international standards is crucial for sourcing reliable Tazarotene API. Due diligence includes audits, documentation review, and compliance assessments.
Supply Chain Resilience: Pandemic-induced disruptions highlight the importance of regional sourcing and flexible supply agreements to ensure consistent API availability.
Cost vs. Quality Balance: While low-cost APIs are attractive, quality and regulatory compliance take precedence to prevent compliance issues and product recalls.
Innovation and Capacity Expansion: The growing demand for dermatological APIs drives investment in manufacturing capacity and technological advancements to improve API purity, efficiency, and environmental profiles.

FAQs

1. What are the primary criteria for selecting a Tazarotene API supplier?
Suppliers must demonstrate GMP compliance, produce high-purity APIs (>98%), provide thorough documentation and Certificates of Analysis, ensure consistent batch quality, and have reliable supply logistics.

2. How does regional manufacturing impact API quality for Tazarotene?
Regional manufacturers in India and China have increased capacity but may vary in regulatory adherence. Rigorous audits and certifications are essential to verify compliance with quality standards before procurement.

3. Are there patent restrictions affecting Tazarotene API sourcing?
While the chemical patent for Tazarotene has long expired in many jurisdictions, licensing agreements or proprietary synthesis routes may influence supplier choices in certain countries.

4. What are the risks associated with low-cost API sources?
Lower-cost suppliers may compromise on quality, purity, or regulatory compliance, risking product recalls, regulatory actions, and damage to brand reputation.

5. How is the supply chain of Tazarotene API expected to evolve?
Increasing regulation, technological advancements, and capacity building are likely to enhance supply stability, quality, and environmental sustainability of Tazarotene API sources.

References

[1] Global API Market Report 2022, Pharmaceuticals Intelligence.
[2] Regulatory Guidelines on API Manufacturing, WHO & EMA.
[3] Chemical and Pharmacological Aspects of Tazarotene, Journal of Dermatology.
[4] Supply Chain Dynamics for Dermatological APIs, Industry Insights.
[5] Sustainable Practices in API Production, Green Pharma Review.

Bulk Pharmaceutical API Sources for TACLONEX